Rapid diagnostics and lateral flow testing underwent the most dramatic expansion in IVD history during the COVID-19 pandemic — and the market is now navigating one of its most significant resets. Rapid antigen test revenues that peaked at over $20 billion in 2021-2022 have normalized sharply as COVID-19 demand subsided, forcing manufacturers to diversify into influenza, RSV, strep, and combination respiratory panels. The underlying lateral flow platform remains one of the most versatile and cost-effective diagnostic technologies — enabling point-of-care testing at the lowest unit cost of any IVD format. Abbott's BinaxNOW, Roche's SARS-CoV-2 portfolio, and QuidelOrtho's Sofia platform demonstrated that consumer-grade rapid tests can achieve mass-market scale. The next growth wave is in multiplexed rapid panels, smartphone-connected readers, and home testing ecosystems.

This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.


Topics Covered
• Rapid Diagnostics and Lateral Flow Market Size and Forecast 2025-2030 by Product and Region
• Post-COVID Market Reset — Revenue Normalization, Portfolio Diversification, and New Growth Drivers
• Respiratory Rapid Testing — Influenza, RSV, COVID-19, and Combination Panels
• Lateral Flow Technology — Membrane Materials, Conjugates, and Reader Integration
• Multiplexed Rapid Tests — Syndromic Panels and Multi-Analyte Platforms
• Home Testing and Consumer IVD — Regulatory Framework and Market Development
• Smartphone-Connected Readers — Digital Integration and Connected Diagnostics
• Competitive Landscape — Abbott, Roche, QuidelOrtho, BD, and Emerging Players
• Regional Analysis — Developed Market Reset vs. Emerging Market Growth
• Investment and Partnership Opportunities — Platform Technology and Distribution